Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells

被引:174
|
作者
Gottipati, Ponnari
Vischioni, Barbara [2 ,3 ]
Schultz, Niklas [4 ]
Solomons, Joyce
Bryant, Helen E. [5 ]
Djureinovic, Tatjana [4 ]
Issaeva, Natalia [4 ]
Sleeth, Kate
Sharma, Ricky A.
Helleday, Thomas [1 ,4 ]
机构
[1] Univ Oxford, Gray Inst Radiat Oncol & Biol, ORCRB, Canc Res UK Med Res Council, Oxford OX3 7DQ, England
[2] Univ Milan, Milan, Italy
[3] European Inst Oncol, Div Radiat Oncol, Milan, Italy
[4] Stockholm Univ, Dept Genet Microbiol & Toxicol, S-10691 Stockholm, Sweden
[5] Univ Sheffield, Inst Canc Studies, Sheffield, S Yorkshire, England
基金
瑞典研究理事会; 英国医学研究理事会;
关键词
DOUBLE-STRAND BREAKS; STALLED REPLICATION FORKS; DNA-REPAIR; MAMMALIAN-CELLS; S-PHASE; CANCER; BRCA2; PATHWAYS; PARP-1; RESISTANCE;
D O I
10.1158/0008-5472.CAN-09-4716
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Poly(ADP-ribose) (PAR) polymerase 1 (PARP1) is activated by DNA single-strand breaks (SSB) or at stalled replication forks to facilitate DNA repair. Inhibitors of PARP efficiently kill breast, ovarian, or prostate tumors in patients carrying hereditary mutations in the homologous recombination (HR) genes BRCA1 or BRCA2 through synthetic lethality. Here, we surprisingly show that PARP1 is hyperactivated in replicating BRCA2-defective cells. PARP1 hyperactivation is explained by the defect in HR as shRNA depletion of RAD54, RAD52, BLM, WRN, and XRCC3 proteins, which we here show are all essential for efficient HR and also caused PARP hyperactivation and correlated with an increased sensitivity to PARP inhibitors. BRCA2-defective cells were not found to have increased levels of SSBs, and PAR polymers formed in HR-defective cells do not colocalize to replication protein A or gamma H2AX, excluding the possibility that PARP hyperactivity is due to increased SSB repair or PARP induced at damaged replication forks. Resistance to PARP inhibitors can occur through genetic reversion in the BRCA2 gene. Here, we report that PARP inhibitor-resistant BRCA2-mutant cells revert back to normal levels of PARP activity. We speculate that the reason for the sensitivity of HR-defective cells to PARP inhibitors is related to the hyperactivated PARP1 in these cells. Furthermore, the presence of PAR polymers can be used to identify HR-defective cells that are sensitive to PARP inhibitors, which may be potential biomarkers. Cancer Res; 70(13); 5389-98. (C) 2010 AACR.
引用
收藏
页码:5389 / 5398
页数:10
相关论文
共 50 条
  • [1] Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells (vol 70, pg 5389, 2010)
    Gottipati, P.
    Vischioni, B.
    Schultz, N.
    Solomons, J.
    Bryant, H. E.
    Djureinovic, T.
    CANCER RESEARCH, 2011, 71 (07) : 2803 - 2803
  • [2] Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
    Jones, Philip
    Wilcoxen, Keith
    Rowley, Michael
    Toniatti, Carlo
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (08) : 3302 - 3314
  • [3] Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective
    Herzog, Thomas J.
    Vergote, Ignace
    Gomella, Leonard G.
    Milenkova, Tsveta
    French, Tim
    Tonikian, Raffi
    Poehlein, Christian
    Hussain, Maha
    EUROPEAN JOURNAL OF CANCER, 2023, 179 : 136 - 146
  • [4] Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition
    Sakogawa, Kenji
    Aoki, Yoshiro
    Misumi, Keizo
    Hamai, Yoichi
    Emi, Manabu
    Hihara, Jun
    Shi, Lin
    Kono, Kazuteru
    Horikoshi, Yasunori
    Sun, Jiying
    Ikura, Tsuyoshi
    Okada, Morihito
    Tashiro, Satoshi
    CANCER SCIENCE, 2013, 104 (12): : 1593 - 1599
  • [5] Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy
    Helleday, T
    Bryant, HE
    Schultz, N
    CELL CYCLE, 2005, 4 (09) : 1176 - 1178
  • [6] Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination
    Schultz, N
    Lopez, E
    Saleh-Gohari, N
    Helleday, T
    NUCLEIC ACIDS RESEARCH, 2003, 31 (17) : 4959 - 4964
  • [7] Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
    McCabe, Nuala
    Turner, Nicholas C.
    Lord, Christopher J.
    Kluzek, Katarzyna
    Bialkowska, Aneta
    Swift, Sally
    Giavara, Sabrina
    O'Connor, Mark J.
    Tutt, Andrew N.
    Zdzienicka, Malgorzata Z.
    Smith, Graeme C. M.
    Ashworth, Alan
    CANCER RESEARCH, 2006, 66 (16) : 8109 - 8115
  • [8] Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers
    Shieh, WM
    Amé, JC
    Wilson, MV
    Wang, ZQ
    Koh, DW
    Jacobson, MK
    Jacobson, EL
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (46) : 30069 - 30072
  • [9] Sensitivity of HPV (+) Oropharyngeal Head and Neck Cancers to Poly (ADP-ribose) Polymerase inhibitor (PARPi), due to Defective Homologous Recombination Repair
    Cha, Y. I.
    Isaeva, N.
    Yarbrough, W. G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S142 - S143
  • [10] Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair
    Bryant, HE
    Helleday, T
    NUCLEIC ACIDS RESEARCH, 2006, 34 (06) : 1685 - 1691